GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?

Franco Locatelli; Concetta Quintarelli

doi:10.1158/1078-0432.CCR-24-0486

GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?

Clin Cancer Res. 2024 Aug 15;30(16):3361-3363. doi: 10.1158/1078-0432.CCR-24-0486.

Authors

Franco Locatelli^{1

2}, Concetta Quintarelli^{1

3}

Affiliations

¹ Department of Hematology/Oncology, Cell and Gene Therapy - IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
² Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
³ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 38869449
DOI: 10.1158/1078-0432.CCR-24-0486

Abstract

Over the past decade, chimeric antigen receptor T cells have emerged as a breakthrough cancer therapy in selected hematologic malignancies. Translating the success of this therapy to solid tumors is challenging. In this issue, we discuss strategies potentially useful to increase the chimeric antigen receptor T-cell efficacy in this clinical indication. See related article by Fischer-Riepe et al., p. 3564.

MeSH terms

Antigens, Neoplasm / immunology
Gangliosides / immunology
Hematologic Neoplasms / immunology
Hematologic Neoplasms / therapy
Humans
Immunotherapy, Adoptive* / methods
Neoplasms* / immunology
Neoplasms* / therapy
Receptors, Antigen, T-Cell / immunology
Receptors, Antigen, T-Cell / metabolism
Receptors, Chimeric Antigen* / immunology
T-Lymphocytes* / immunology

Substances

Receptors, Chimeric Antigen
Gangliosides
ganglioside, GD2
Antigens, Neoplasm
Receptors, Antigen, T-Cell